Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

anxiety

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

ONLY AVAILABLE IN PAID PLANS.

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase/article_17520fd3-203b-5e31-8c49-0731ba5de28d.html